Other Clinical Trial - Pneumatic Retinopexy Versus Vitrectomy for Retinal

Status Recruiting

Clinical Trial Summary

Objective: To compare outcomes of retinal detachment repair following pneumatic retinopexy (PnR) versus pars plana vitrectomy in terms of anatomical success, functional success and patient quality of life in patients with extended criteria.

Methods: A prospective, randomized, controlled trial will be conducted with 178 patients presenting at St. Michael's Hospital with primary retinal detachment (RD). Inclusion criteria include: a single or multiple retinal tears in detached retina between 7 and 5 o'clock being of any size and any distance apart from each other, including giant retinal tears with inferior aspect above 5 and 7 o'clock, RD with no identifiable tear but where suspected tear is between 7 and 5 o'clock, retinoschisis with RD if tears are located between 7 and 5 o'clock, mild proliferative vitreoretinopathy, none or mild vitreous hemorrhage. Patients will be excluded if there is a small retinal tear or multiple tears less than 30o apart between 8 and 4 o'clock in detached retina, retinal tear in detached retina between 5 and 7 o'clock, <18 years old, inability to read English, mental incapacity, previous history of RD, scleral buckle or vitrectomy in index eye, inability to maintain appropriate head posture at post-operative period and inability to visualize peripheral retinal due to media opacity. Patients will be randomly allocated into two groups: PnR + cryotherapy/laser or vitrectomy + cryotherapy/laser and the intervention will take place within 24 hours and 72 hours for attached and detached macula status, respectively. Patients will undergo a complete ophthalmological examination, including visual acuity and fundus assessment at baseline and at 3, 6 and 12 months after surgery. Visual acuity will also be measured at 1, 7 and 30 days after surgery. Global health related quality of life will be evaluated with the SF-36v2 questionnaire at baseline, 1 month, 1 and 2 years after intervention, while the VFG25 questionnaire will be applied at 3, 6, 12 and 24 months after surgery to measure vision related quality of life.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Dissociative Disorders
Retinal Detachment
Rhegmatogenous Retinal Detachment

Clinical Trial Details

NCT number	NCT02871531
Study type	Interventional
Source	St. Michael's Hospital, Toronto
Contact	Rajeev Muni, MD
Phone	416-867-7411
Email	rajeev.muni@utoronto.ca
Status	Recruiting
Phase	N/A
Start date	November 2016
Completion date	November 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04403750` - Combined Laser-surgical Technology of RRD Treatment	N/A
Not yet recruiting	`NCT04520789` - Early Prevention Strategies of Severe Proliferative Vitreoretinopathy Base on Precision Diagnosis of Single Cell Sequencingvitreoretinopathy	N/A
Recruiting	`NCT04571788` - Treating Rhegmatogenous Retinal Detachment by Foldable Capsular Buckle
Completed	`NCT02834559` - Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.	Phase 3
Recruiting	`NCT01845571` - Retinal Detachment - Demographic and Clinical Survey
Completed	`NCT04891991` - Intravitreal Infliximab for Proliferative Vitreoretinopathy	Phase 2
Completed	`NCT00757536` - Primary Vitrectomy With Endolaser or Encircling Band for Rhegmatogenous Retinal Detachment	N/A
Active, not recruiting	`NCT00370201` - Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment	Phase 3
Completed	`NCT00345007` - Macular Function After Scleral Buckle	N/A
Recruiting	`NCT05331664` - Dropless Pars Plana Vitrectomy Study	Phase 4
Completed	`NCT02841306` - Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment	Phase 1
Not yet recruiting	`NCT02185469` - Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment	N/A
Not yet recruiting	`NCT01647373` - Axial Length Change in Eyes Treated by Silicone Sponge Scleral Buckling	N/A
Completed	`NCT01068379` - Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation	Phase 3
Not yet recruiting	`NCT06425419` - The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy	Phase 1
Not yet recruiting	`NCT06468397` - Acute Retinal Detachment Repair With the iSeelr^TM Retinal Detachment Repair System	N/A
Recruiting	`NCT06056596` - Lamivudine and Plasma Markers of Inflammation in Retinal Detachment	Early Phase 1
Completed	`NCT01343134` - Anatomical and Functional Macular Changes in Retinal Detachment	N/A
Recruiting	`NCT05588037` - Combined Vitrectomy and Femtosecond Laser-assisted Cataract Surgery	N/A
Completed	`NCT03542162` - Healaflow Patch for the Treatment of Rhegmatogenous Retinal Detachment	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Pneumatic Retinopexy Versus Vitrectomy for Retinal Detachment in Patients With Extended Criteria

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms